Molecular Partners AG
(NASDAQ : MOLN)

( )
MOLN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.72%174.070.0%$1639.17m
NVAXNovavax, Inc. -6.21%92.3378.2%$633.32m
AMGNAmgen, Inc. -1.08%231.301.4%$520.34m
BIIBBiogen, Inc. -1.28%230.811.8%$499.50m
GILDGilead Sciences, Inc. -1.93%69.071.0%$465.79m
BNTXBioNTech SE -4.47%161.660.0%$438.57m
REGNRegeneron Pharmaceuticals, Inc. 1.13%618.112.7%$392.67m
ILMNIllumina, Inc. 0.32%384.363.3%$386.08m
VRTXVertex Pharmaceuticals, Inc. -0.10%230.841.9%$334.35m
SNSSSunesis Pharmaceuticals, Inc. -4.00%2.880.7%$201.32m
EXASEXACT Sciences Corp. -1.67%76.1317.9%$160.64m
ARNAArena Pharmaceuticals, Inc. -0.51%91.5113.7%$138.71m
ALNYAlnylam Pharmaceuticals, Inc. -0.41%138.628.2%$131.51m
INCYIncyte Corp. -0.31%74.782.4%$129.60m
BBIOBridgeBio Pharma, Inc. -0.51%11.700.0%$104.26m

Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.